Fresenius Medical Care AG（FMS）财务数据FMSFresenius Medical Care AG

Fresenius Medical Care AG (FMS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Care Delivery, accounting for 68.8% of total sales, equivalent to $3.71B. Other significant revenue streams include Care Enablement and Value based care. Understanding this composition is critical for investors evaluating how FMS navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Fresenius Medical Care AG maintains a gross margin of 26.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.13%, while the net margin is 6.03%. These profitability ratios, combined with a Return on Equity (ROE) of 7.23%, provide a clear picture of how effectively FMS converts its operational activities into shareholder value.

In the context of the broader market, FMS competes directly with industry leaders such as ENSG and DVA. With a market capitalization of $11.21B, it holds a significant position in the sector. When comparing efficiency, FMS's gross margin of 26.95% stands against ENSG's 14.47% and DVA's 27.98%. Such benchmarking helps identify whether Fresenius Medical Care AG is trading at a premium or discount relative to its financial performance.

Fresenius Medical has shown a gross margin improvement to 26.95% in Q2 2026, up from 24.98% in Q4 2024, reflecting better operational efficiency. However, the net income for Q2 2026 was $253.72 million, which is lower than the peak of $380.73 million in Q4 2025, indicating some volatility in profitability.